<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188665</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2019000548</org_study_id>
    <nct_id>NCT04188665</nct_id>
  </id_info>
  <brief_title>Using MASL to Combat Oral Cancer</brief_title>
  <official_title>Using MASL to Combat Oral Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rowan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rowan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells
      from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer
      cells are to a potential drug called Maackia amurensis seed lectin (MASL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-treatment OSCC morphology and PDPN expression</measure>
    <time_frame>1 day to 4 weeks.</time_frame>
    <description>Measure morphology and podoplanin (PDPN) expression by immunohistochemistry of cells included in initial biopsies of oral lesions in comparison to normal oral squamous epithelial cells (OSCCs). We will select patients with lesions that express robust levels of PDPN and notable dysplasia for inclusion in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-treatment OSCC morphology and PDPN expression</measure>
    <time_frame>1 day to 4 weeks.</time_frame>
    <description>Evaluate and compare the PDPN expression and morphology of cells from included in resected oral lesions from patients treated with the experimental compound MASL or placebo. We will measure if MASL treatment decreases PDPN expression and normalizes morphology of OSCC cells on a defined scale of pathological examination by immunohistochemistry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>MASL treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with lozenge containing MASL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treated</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with lozenge without MASL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MASL</intervention_name>
    <description>Patients treated with MASL lozenge</description>
    <arm_group_label>MASL treated</arm_group_label>
    <other_name>Maackia amurensis seed lectin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients treated with placebo lozenge</description>
    <arm_group_label>Placebo treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females of at least 18 years of age who are able to give consent.

          2. Smokers and non-smokers.

          3. Persons with white or red spots and/or lesions suspected or found to be oral cancer or
             precancer on the inner surface of the mouth.

          4. Oral lesions will be classified as OSCC or leukoplakia including, proliferative
             verrucous leukoplakia, conventional erythroplakia, suspect oral papillomas, or oral
             lichen planus. Only patients with such histologically confirmed diagnoses will be
             considered for inclusion.

          5. patients will be considered for inclusion at any stage of disease progression.

          6. Patients will be considered for inclusion if a subsequent biopsy or surgical resection
             are planned as part of their best care treatment.

          7. Patients will have an Eastern Cooperative Oncology Group performance status of 0 or 1.

          8. Patients will display normal organ function as evidenced by standard laboratory blood
             tests including liver enzymes and creatine.

          9. Patients will not present evidence of comorbidities including ongoing or active
             infection, unstable illness, or medical conditions.

        Exclusion Criteria:

          1. Patients with cognitive impairments and cannot consent for themselves.

          2. Patients with language/hearing impairments.

          3. Use of a topical steroid product within the last 2 weeks.

          4. Pregnant women (to avoid any potential risk to the fetus) to be confirmed by standard
             blood or urine tests according to best care practice.

          5. Patients who are breastfeeding.

          6. Abstinence or use of adequate contraception will be required for women of childbearing
             potential and men of reproductive potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GARY S GOLDBERG</last_name>
    <phone>8565666718</phone>
    <email>gary.goldberg@rowan.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahnaz Fatahzadeh</last_name>
    <phone>9739721956</phone>
    <email>fatahza@sdm.rutgers.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mahnaz Fatazadeh, DMD, MSD</last_name>
      <phone>973-972-1956</phone>
      <email>fatahza@sdm.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers School for Dental Medicine</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mahnaz Fatahzadeh, DMD, MSD</last_name>
      <phone>973-972-1956</phone>
      <email>fatahza@sdm.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mahnaz Fatazadeh, DMD, MSD</last_name>
      <phone>973-971-1956</phone>
      <email>fatahza@sdm.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rowan University</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <zip>08084</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>GARY GOLDBERG, PhD</last_name>
      <phone>856-566-6718</phone>
      <email>gary.goldberg@rowan.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maackia amurensis</keyword>
  <keyword>podoplanin</keyword>
  <keyword>pdpn</keyword>
  <keyword>lectin</keyword>
  <keyword>oral squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

